PAR — Paradigm Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall Cap
- AU$143.29m
- AU$135.35m
- AU$8.12m
Australia's Paradigm Biopharmaceuticals jumps on U.S. FDA nod for clinical trial
Brief: Paradigm Biopharmaceuticals Says U.S FDA Cleared IND Application To Proceed With Phase 3 Trial
Australia Stock Exchange release from PARADIGM BIOPHAR : PARADIGM CLEARED FOR PHASE 3 TRIAL BY US FDA
Australia Stock Exchange release from PARADIGM BIOPHAR : PRE_NR Ends: 09:06:34
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia Stock Exchange release from PARADIGM BIOPHAR : Trading Halt
Australia Stock Exchange release from PARADIGM BIOPHAR : Date of Annual General Meeting
Australia Stock Exchange release from PARADIGM BIOPHAR : PRE_NR Ends: 09:04:31
Australia Stock Exchange release from PARADIGM BIOPHAR : Quarterly Update and Appendix 4C - quarterly
AU's Paradigm Biopharmaceuticals jumps as co gets Phase II study approval
Australia Stock Exchange release from PARADIGM BIOPHAR : PRE_NR Ends: 09:32:43
Australia Stock Exchange release from PARADIGM BIOPHAR : Phase 2 Synovial Fluid Biomarker Study Update
Australia Stock Exchange release from PARADIGM BIOPHAR : PRE_NR Ends: 08:40:42
Australia Stock Exchange release from PARADIGM BIOPHAR : POSITIVE TOP-LINE RESULTS FROM PRECLINICAL STUDY IN ARDS
Australia Stock Exchange release from PARADIGM BIOPHAR : FIRST MPS-VI PATIENT DOSED UNDER PHASE 2 TRIAL IN BRAZIL
Australia Stock Exchange release from PARADIGM BIOPHAR : PRE_NR Ends: 10:45:05
Australia Stock Exchange release from PARADIGM BIOPHAR : PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION
Australia Stock Exchange release from PARADIGM BIOPHAR : PRE_NR Ends: 08:34:30
Brief: Paradigm Biopharma Gets Australian Ethics Approval For Phase 3 Trial For PARA_OA_002